Résumé
Background: New therapeutic approaches, particularly anti-vascular endothelial growth factor (anti-VEGF) therapies, prevent, and in some cases reverse, vision damage caused by age-related macular degeneration (AMD). Unequal access to care across Canada remains a problem for many retina specialists and their patients. Objective: To develop a consensus concerning the management of patients with exudative age-related macular degeneration (AMD). Design: Consensus document. Participants: Ten Canadian retina specialists. Methods: The development of a consensus among Canadian experts concerning optimal treatment of AMD began with a review of the clinical evidence, daily practices, existing guidelines, and current national and international approvals and policies. The experts met on June 29, 2010, in Quebec City to discuss their findings and to propose strategies for consensus. Results: The result of this expert panel is a consensus proposal for Canadian ophthalmologists and retina specialists who are treating patients with or at risk for developing neovascular AMD. Conclusions: The consensus provides guidelines to aid retina specialists in managing exudative AMD. Currently, ranibizumab is the only agent with sufficient Level I evidence and a Health Canada-approved indication for the treatment of wet AMD. Bevacizumab has been shown to be noninferior in preserving and improving visual acuity when compared to ranibizumab. Potential safety differences between the 2 drugs remain to be elucidated. The positioning of ranibizumab in this therapeutic area will be further defined as additional data for existing and emerging therapies become available. Until then, this agent remains the therapy of choice for individuals with neovascular AMD.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 227-235 |
| Nombre de pages | 9 |
| Journal | Canadian Journal of Ophthalmology |
| Volume | 47 |
| Numéro de publication | 3 |
| DOI | |
| Statut de publication | Published - juin 2012 |
Note bibliographique
Funding Information:A.C. holds no equity position with any pharmaceutical company. He has received consulting fees for advisory board meetings and honoraria for speaking engagements from a number of entities, including Alcon, Novartis, and Pfizer. A.B. has received honoraria from Novartis Ophthalmics Canada, Alcon Canada, Bayer Canada, and Bausch and Lomb. He is the National Principal Investigator for the RESPOND clinical trial on diabetic macular edema, which is sponsored by Novartis Ophthalmics. St. Michael's Hospital receives unrestricted educational grants from Novartis Ophthalmics Canada and Alcon Canada . K.C. has received consultant funding from Bayer and Novartis and research funding and speaker fees from Novartis. M.G. is a consultant for Novartis (ACUITY program) and Bausch & Lomb. P.H. has no conflict of interest to disclose in relation to the content of this document. P.K. has received research funding from Novartis, Bayer/Regeneron, and GlaxoSmithKline. He is a consultant for Bausch & Lomb and Arctic Dx and has received honoraria from Alcon, Allergan, Novartis, and Bayer. T.S. has been a paid advisory panel member for Novartis, QLT, and Pfizer. He has also received research funding from Novartis, QLT, and Pfizer and is co-Principal Investigator for the RESPOND trial in diabetic macular edema. E.T. is a paid consultant for Alcon, Novartis, Allergan, and Bausch & Lomb. He has received speaker honoraria from Alcon, Novartis, Allergan, Bausch & Lomb, and Pfizer as well as honoraria to conduct clinical research for Novartis. G.W. has been a consultant or advisory board participant and has been involved in clinical trials for Pfizer, Novartis, Regeneron, Allergan, MD Collaborate, Arctic Dx, and Bausch & Lomb. D.W. is a consultant for Novartis, Labtician, Diagnos, Bayer, MD Collaborate, Alcon, Arctic DX, and Allergan. He has received research funding from Novartis, QLT, and Alcon.
Funding Information:
The meeting was organized by SNELL Medical Communication Montreal, PQ). and funding for the meeting, including a single night's accommodation, was provided as an unrestricted grant from Novartis Pharmaceuticals Canada . Honoraria were provided to the participants to develop and present slides to generate discussion.
ASJC Scopus Subject Areas
- Ophthalmology
PubMed: MeSH publication types
- Consensus Development Conference
- Journal Article